Novartis Contracts with Cryoport to Support Novartis Cell Therapies
Irvine, CA – July 25, 2017 - Cryoport (Cryoport or the company) announced that Novartis has signed an agreement contracting Cryoport over an initial three-year term for cryogenic logistics support of CTL019/CD19 CAR-T cell therapy.
Cryoport’s cryogenic logistics solutions are designed to meet Novartis’ expanding cryogenic logistics requirements, including the use of its Cryoport Express® shippers, SmartPak IITM Condition Monitoring System, CryoportalTM Logistics Management Platform, which includes chain-of-condition and chain-of-custody monitoring, and 24/7/365 logistics support.
On March 29th, 2017 Novartis announced that the FDA had accepted their first Biologics License Application for CTL019 and that it was also granted priority review by the FDA. Now, Novartis has selected Cryoport for its clinical and commercial logistics support.
Jerrell Shelton, CEO of Cryoport, stated, “We are proud that Novartis has chosen Cryoport to support the clinical studies and the commercialization of its CLT019. This is a milestone for Cryoport. Our Novartis agreement is a good example of how our clinical trial agreements with biopharma clients can drive substantial revenue growth for Cryoport as therapies move through the stages of clinical trials to commercialization. Currently, we are supporting over 140 clinical trials in the regenerative medicine space with 17 of these biopharma clients in Phase III. We enjoy meeting Novartis’s exacting requirements and are delighted to have this commercial agreement in place.”
For more information, visit www.cryoport.com. Sign up to follow @cryoport on Twitter at www.twitter.com/cryoport.
Investor Contacts:
Todd Fromer/Elizabeth Barker
tfromer@kcsa.com/ebarker@kcsa.com
P: 1 212-682-6300
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
